about
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionEffects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRIPopulation Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
P2860
Q24651239-4588014F-8AA9-41B8-A2BE-AC02AE100ACDQ28475976-C5D95C15-84D7-4D52-99BB-48C6430D0A74Q33712655-A6F6ED80-9514-4A8A-8B2E-1B994C84B1BDQ35793641-4EEF038C-B13C-4618-8CAA-1573E9A7096DQ35903844-358B509B-B73A-450D-98C2-1234B090C58FQ35967888-9A361D57-492F-4E7F-9123-13D0C8CF6D29Q36113188-D6AD8BEB-2961-4E36-965C-54B965775E39Q36510493-2F1B4933-5359-4CD7-BA43-A1D83B04516CQ36684423-2FDF1665-3133-461C-80B9-A07EEF5E85C8Q36806579-0736C6F3-7C80-4DF5-93AE-FE442E8BB4AAQ36968457-CB427BB1-71A8-40C4-904A-7630FEA228D3Q38391227-CF43EDAE-3F3E-4843-8D5E-A826F214C7F1Q42700517-8750D7BA-E7F0-4462-B603-2C0E45194888Q43288450-C2571FCE-5DF3-4E3E-B206-4682A70AD1D4Q43903895-48495866-0E7B-407E-8FCD-1CCBCB0FE2D0Q51744122-AC5D79AC-DA90-4C93-B4D4-6718D1BC00B3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetic pathway analysis of irinotecan.
@en
Pharmacogenetic pathway analysis of irinotecan.
@nl
type
label
Pharmacogenetic pathway analysis of irinotecan.
@en
Pharmacogenetic pathway analysis of irinotecan.
@nl
prefLabel
Pharmacogenetic pathway analysis of irinotecan.
@en
Pharmacogenetic pathway analysis of irinotecan.
@nl
P2093
P2860
P356
P1476
Pharmacogenetic pathway analysis of irinotecan.
@en
P2093
F Innocenti
G L Rosner
J C Panetta
M J Ratain
P2860
P304
P356
10.1038/CLPT.2008.63
P407
P577
2008-04-16T00:00:00Z